Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. International Trade Commission [Investigation No. 332-520] AGENCY: United States International Trade Commission. ACTION: Institution of investigation and invitation to file written submissions. SUMMARY: Following receipt of a request dated May 27, 2010 from the United States Trade Representative (USTR) pursuant to section 115 of the Uruguay Round Agreements Act (URAA) ( 19 U.S.C. 3524 ) and section 332(g) of the Tariff Act of 1930 ( 19 U.S.C. 1332 (g)), the U.S. International Trade Commission (Commission) instituted investigation No. 332-520, Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain ( printed page 33825) Products to the Pharmaceutical Appendix to the HTS. DATES: July 14, 2010: Deadline for filing all written submissions. September 1, 2010: Transmittal of Commission report to the United States Trade Representative. ADDRESSES: All Commission offices, including the Commission's hearing rooms, are located in the United States International Trade Commission Building, 500 E Street SW., Washington, DC. All written submissions should be addressed to the Secretary, United States International Trade Commission, 500 E Street, SW., Washington, DC 20436. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at http://www.usitc.gov/​secretary/​edis.htm . FOR FURTHER INFORMATION CONTACT: Information specific to this investigation may be obtained from Philip Stone, Pr…